Use of botulinum toxin type a for chronic cough: A neuropathic model

Archives of Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 5, 2010, Pages 447-452

  Chu, Michael W ^a   Lieser, John D ^b   Sinacori, John T ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Ear Nose and Throat Center of Fredericksburg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NEUROPEPTIDE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ASSESSMENT; COUGHING; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LARYNX SPASM; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEUROGENIC INFLAMMATION; NEUROPATHY; OUTCOME ASSESSMENT; PHONATION; PHYSICAL EXAMINATION; QUALITY OF LIFE; STROBOSCOPY; TRACHEOSTOMY; TREATMENT DURATION; VOICE;

ADULT; BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; COUGH; ELECTROMYOGRAPHY; FEMALE; HUMANS; INJECTIONS; LARYNGISMUS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77952527338     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2010.59     Document Type: Article

References (23)

1. Altman KW, Simpson CB, Amin MR, Abaza M, Balkissoon R, Casiano RR. Cough and paradoxical vocal fold motion. Otolaryngol Head Neck Surg. 2002;127(6):501-511.
2. Irwin RS, Boulet L-P, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians. Chest. 1998;114(2)(suppl):133S-181S.
3. Andrianopoulos MV, Gallivan GJ, Gallivan KH. PVCM, PVCD, EPL, and irritable larynx syndrome: what are we talking about and how do we treat it? J Voice. 2000;14(4):607-618.
4. Amin MR, Koufman JA. Vagal neuropathy after upper respiratory infection: a viral etiology? Am J Otolaryngol. 2001;22(4):251-256.
5. Rees CJ, Henderson AH, Belafsky PC. Postviral vagal neuropathy. Ann Otol Rhinol Laryngol. 2009;118(4):247-252.
6. Cukier-Blaj S, Bewley A, Aviv JE, Murry T. Paradoxical vocal fold motion: a sensorymotor laryngeal disorder. Laryngoscope. 2008;118(2):367-370.
7. Sipp JA, Haver KE, Masek BJ, Hartnick CJ. Botulinum toxin A: a novel adjunct treatment for debilitating habit cough in children. Ear Nose Throat J. 2007;86(9):570-572.
8. Morrison M, Rammage L, Emami AJ. The irritable larynx syndrome. J Voice. 1999;13(3):447-455.
9. Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope. 2006;116(12):2108-2112.
10. Visser LE, Stricker BH, van der Velden J, Paes AH, Bakker A. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol. 1995;48(6):851-857.
11. Trifilieff A, Da Silva A, Gies JP. Kinins and respiratory tract diseases. Eur Respir J. 1993;6(4):576-587.
12. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1)(suppl): 169S-173S.
13. Chang AB. Cough, cough receptors, and asthma in children. Pediatr Pulmonol. 1999;28(1):59-70.
14. Jordan D. Central nervous mechanisms in cough. Pulm Pharmacol. 1996;9(5-6):389-392.
15. Bastian RW, Vaidya AM, Delsupehe KG. Sensory neuropathic cough: a common and treatable cause of chronic cough. Otolaryngol Head Neck Surg. 2006;135(1):17-21.
16. Kyrmizakis DE, Pangalos A, Papadakis CE, Logothetis J, Maroudias NJ, Helidonis ES. The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg. 2004;62(7):840-844.
17. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993;52(3):259-285.
18. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm. 2006;63(2):145-152.
19. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1990;40(9):1332-1336.
20. Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ. 2005;172(1):69-75.
21. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274-283.
22. Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003;250(2):188-193.
23. Nichols ML, Allen BJ, Rogers SD, et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science. 1999;286(5444):1558-1561.